StockWatch
·
COFORGE LTD · QQ1 FY-2027 · THE CALL

Record order book drives long-term upside; near-term margins pressured by integration

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 resultsCOFORGECoforge Ltd02 Aug 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Hit 15.5% EBIT guidance in Q1 (delivered 16.0% consolidated), but standalone Coforge at 16.7% masks 2-month Encora contribution. Prior FY26 guidance reaffirmed. One-time costs ($24M Q1) acknowledged and expected to decrease Q2+. Order book track record strong.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Coforge delivered revenue growth (+50% YoY) and order book momentum ($2.23B, +44% YoY) ahead of peers, supported by strong AI positioning (86% revenue). However, near-term margins are pressured by Encora integration costs ($6.5M/quarter) and hedge losses ($10M Q1, $14M MTM), causing QoQ PAT to decline 20.2% despite 49.9% YoY revenue growth. PAT growth (49.2% YoY) lags revenue growth, signaling margin headwinds. Management reaffirmed 15.5%+ EBIT guidance for FY27 (already at 16.0% in Q1, but this includes only 2 months of Encora at 19% EBIT, masking near-term dilution). Key risk: deal ramps (especially $230M deal signed for Q2) must execute on schedule to justify current growth narrative; margin recovery dependent on integration cost normalization by Q3.

₹5527.7 Cr

Revenue · +49.9% YoY

₹531.7 Cr

Reported PAT · +49.2% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Revenue up 49% YoY; organic growth 5.2% CC sequential ex-closures

MET

₹5527.7 Cr delivered (+49.9% YoY); organic CC growth 1.1% reported, 5.2% ex-India govt/data center exits

Combined entity Q1 EBIT 16.0%, meeting/exceeding 15.5% FY27 guidance

MET

Consolidated EBIT 16.0% confirmed; standalone Coforge 16.7%; but Q1 includes only 2 months Encora ($100.7M revenue at 19.1% EBIT)

PAT up 110% YoY; NPM expansion of 271 bps

OVERSTATED

Delivered PAT growth 49.2% YoY; NPM 9.6% vs likely ~6.5% prior year (implied 300+ bps expansion, not 271). Management's 110% figure appears standalone/adjusted; consolidated delivered is 49.2%

Order book $2.23B, +44.2% YoY; 4 large deals signed in Q1

MET

Order book confirmed at $2.23B vs $1.55B year ago; 4 large deals signed substantiated (e.g., $158M deal ramped, $230M deal announced for Q2)

Encora integration ahead of plan; 40% G&A cost reduction achieved

MET

Encora G&A reduced from 10% to 6.6% combined (40% reduction confirmed); all 45 legal entities migrated to SAP S/4HANA by May 1; delivered 19.1% EBIT vs expected margin accretion

Earnings quality

What changed since the last call

Deltas vs. the prior call

Order book +44% YoY (vs 30% prior guidance)

Upgrade

Prior FY26 guidance expected order book +30%; delivered $2.23B is +44% YoY vs $1.55B year ago. Four large deals signed in Q1 + $230M deal announced; deal momentum exceeding expectations.

EBIT margin guidance maintained, Q1 ahead

Upgrade

Prior guidance 15.5% consolidated FY27 EBIT; Q1 delivered 16.0% (40 bps ahead). Standalone Coforge 16.7% (vs 16.5-17% guidance range, at top end). But diluted by Encora 2-month contribution and integration costs.

Encora synergies realized faster than guided

Upgrade

Prior guidance expected Encora margin accretion by Q3; delivered 40% G&A cost reduction by Q1, 19.1% EBIT within 2 months, ahead of integration playbook. System migrations (SAP S/4HANA) completed by May 1.

PAT growth narrative tempered by one-time costs

Neutral

Prior guidance 'exceptional' FY27 growth; Q1 delivered 49.2% PAT YoY growth (strong), but QoQ declined 20.2% due to $24M one-time/integration costs. Normalized for comparability, underlying growth solid but not exceptional near-term.

AI revenue mix exceeded; 86% vs 80% target

Upgrade

Prior Encora announcement indicated 80% AI-led revenue (Engineering, Data, Cloud); delivered 86% in Q1, driven by Encora's 100% engineering mix (no cloud revenues). Mix quality higher than guided.

The Q&A

Analyst questions focused on three themes: (1) whether 5.2% organic growth would continue (pushed back: no hard guidance, expecting 'robust' Q2 but dependent on deal ramps); (2) margin-vs-growth trade-off (defended: solution-led selling doesn't warrant discounting, can achieve both; already at 16% EBIT and targeting industry-leading margins); (3) Encora order book trajectory (deflected: only 2 months data, will share Q2 update; overall pipeline 'robust'). Management held firm on guidance, acknowledged one-time costs, deflected on specific deal-by-deal profitability. Tone professional but slightly defensive on margin compression justification.

The exchanges that mattered

Order intake composition — Sulabh Govila, Morgan Stanley

Answered

$691M is standalone Coforge organic only (excludes Encora). UK framework agreements still not included; will sit on top of reported order intake. $230M deal (announced post-call) also not in this number.

Large deal revenue ramp timing — Sulabh Govila, Morgan Stanley

Answered

Q2 will be robust; many deals already closed in first month; ramps mostly start Q3+. Expected sequential 5.2% CC growth in Q1 ex-closures; Q2 should be very robust despite most ramp benefit delayed.

AI monetization & platforms — Abhishek Pathak, Motilal Oswal

Partial

Nuuron is operating layer, not standalone platform. 30% of active engagements infused with AI assets. 86% revenue is AI-led (Engineering, Cloud, Data). 6-7% of revenue from outcome-based contracts. Cannot isolate platform-only revenue; blended into service lines.

Margin-growth tradeoff — Abhishek Pathak, Motilal Oswal

Answered

Solution-led selling doesn't warrant price discounting. Targeting industry-leading growth (third-year running) AND highest margin mid-cap simultaneously; both possible. Standalone Coforge 16.7% EBIT, consolidated 16%.

Enterprise AI adoption vs industry trends — Vibhor Singhal, Nuvama Equities

Answered

Smart enterprises avoiding lock-in to single LLM/cloud; moving to sovereign/open AI. Service offerings around token ops, security partnerships (Zscaler Guardian AI). Our edge is applied AI in complex domains, not model ownership. Context > models.

Encora large client opportunity — Prateek Maheshwari, HSBC

Answered

One Encora client already in top 10 (scalable to $50M+ in 12-18 months). Two accounts in 11-20 range (e.g., Travel portfolio, can scale rapidly). Execution discipline and cross-selling will drive scaling.

G&A cost structure post-acquisition — Ravi Menon, Axis Capital

Answered

G&A down as % of revenue (6.6% combined vs 6.7% Coforge + 10% Encora). Absolute increase due to Encora consolidation; 40% Encora G&A reduction already achieved. Further reduction expected in Q2.

FCF seasonality improvement — Vibhor Singhal, Nuvama Equities

Answered

Structurally improved FCF trajectory over 2-3 years (H1 historically near zero; now strong). Confident trend will continue; targeting 100%+ FCF-PAT for FY27.

Working capital and NWC trends — Sulabh Govila, Morgan Stanley

Answered

Absolute increase is Encora consolidation; days have actually come down. No structural working capital deterioration.

Outcome-based contract pricing — Aditi Patil, ICICI Securities

Answered

Three models: (1) legacy modernization on risk basis (lower effort revenue, supernormal post-success profits via Forge-X/Nuuron); (2) subscription model for Mod Squads (monthly, flex FTEs/agents); (3) tech/business outcome-tied models. 6-7% of revenue.

Encora order book and ramp timeline — Divyesh Mehta, Invesco India

Partial

Only 2-month Encora data ($100.2M revenue); order intake was robust, pipeline robust. Not enough data to divvy separately. Margins already indistinguishable (40% G&A cut). Revenue growth indistinguishable by Q3 (not 4 quarters; 2 quarters).

Guidance

Forward guidance and management's confidence

FY27 'exceptional growth' (no specific %), order book +44% YoY ($2.23B)

High

Q1 delivered 49.9% YoY revenue growth. Order book significantly ahead of 30% prior expectation. Four large deals signed Q1, $230M deal announced Q2. Large deal ramps Q2-Q3 expected to drive full-year momentum

Consolidated EBIT 15.5%+ FY27 (Q1 delivered 16.0%)

High

Standalone Coforge 16.5-17% (Q1 at 16.7%); Encora 19.1% EBIT (Q1, 2 months). Guidance reaffirmed despite one-time integration costs ($6.5M Q1) and hedge impacts ($24M). Encora synergies delivering; G&A now 6.6% combined

EBITDA 20.5-21% consolidated FY27 (inferred Q1 ~18-19%)

Medium

Guidance consistent with prior call. Q1 impacted by $40M/year intangible amortization (customer relationship intangibles from Encora $480M amortized 12yr). Margin sustainable if deal ramps and cost normalization execute

No explicit capex guidance; FCF guidance 100%+ FCF-PAT

High

Q1 delivered 95.3% FCF-PAT conversion (vs -56.5% prior year). Structural WC improvement targeting 100%+ for FY27. No major capex requirements flagged; asset-light model maintained

Risks the call surfaced

Ranked by how much they should concern a holder

Deal ramp execution

High

Four large Q1 deals + $230M Q2 deal (largest announced) ramps 'just initiated.' Revenue depends on FTE deployment pace, customer acceptance, and transition milestones. If ramps slip or require higher delivery costs, revenue misses and margin compression risk

Margin normalization & one-time costs

High

Q1 PAT declined 20.2% QoQ despite 24.2% revenue growth due to $24M one-time/integration costs ($6.5M acquisition, $10M hedge loss, $14M MTM loss to be realized Q2-Q3). Intangible amortization ($40M/year permanent) and finance costs on $550M term loan (2.99% post-tax) will persist. If normalization slows or deal margin profiles underperform, 15.5% EBIT guidance at risk

Encora margin sustainability

Medium

Encora delivered 19.1% EBIT in Q1 (2-month window May-June); likely captured higher-margin ramp and seasonal tailwinds. Full-quarter and annual run-rate unknown. If Encora normalized margins drop to 16-17% (near consolidated target), blended margin upside diminishes. Also, $480M customer relationship intangibles ($40M/year amortization) will drag reported EBIT

Organic growth moderation

Medium

Organic CC sequential growth only 1.1% reported (5.2% ex-India govt/data center exits). This is below company's historical 20%+ CAGR and below 'robust growth' rhetoric. Suggests base business softness; reliance on large deal ramps to drive FY27 growth. If deal ramps compress or discretionary spending weakens industry-wide, full-year growth guidance at risk

Valuation & market multiple compression

Medium

Management has guided 'exceptional' FY27 growth and 'highest margin mid-cap' positioning, implying premium valuation expectations. However, delivered results show PAT growth (49.2% YoY) lagging revenue growth (49.9% YoY) and QoQ PAT declining 20.2%, signaling near-term margin pressure. If large deal ramps disappoint or one-time costs persist longer than guided, multiple compression risk

Management

Score 8/10. Clear and structured; Sudhir Singh leads with 10-year tenure recap, strategic AI positioning (Nuuron, Enterprise Autonomy), and specific deal examples. Acknowledges one-time costs transparently. Deflects on Encora order book details (only 2-month data) but promises Q2 update. Avoids hard Q2/Q3 guidance (uses 'robust' instead of %); justifiable given deal ramp timing uncertainty Strong: 9-year 21.7% revenue CAGR, 24.1% PAT CAGR. Delivered order book +44% YoY (beat 30% expectation). Encora integration 40% G&A reduction ahead of plan. $158M deal ramped in 4 months to 300+ FTEs. FY26 guidance met/beat. Q1 EBIT 16.0% ahead of 15.5% FY27 target. Track record of acquisition success (Cigniti, SLK Global, Incessant) credible

What to watch next
  • 1 · Q2 FY27

    $230M multi-year deal ramps; 20-30 additional teams; full revenue recognition tracking

  • 2 · Q2 FY27

    Integration cost normalization; hedge impacts reduce; standalone margins expand toward 17%

  • 3 · Q3 FY27

    Encora order book ramp; large deals in 11-20 client list scale from ₹20-50Cr to $50M+ buckets

Key risk: deal ramps (especially $230M deal signed for Q2) must execute on schedule to justify current growth narrative; margin recovery dependent on integration cost normalization by Q3.

Informational and educational content only. Not investment advice.